Skip to main content

Table 4 Intergroup comparisons of clinical and radiographic parameters between OP group, osteopenia group and normal group

From: The correlation between volumetric bone mineral density and morphological parameters of the proximal femur and clinical outcomes in ankylosing spondylitis patients with hip involvement

Characteristics

OP group (n = 8)

Osteopenia group (n = 28)

Normal group (n = 29)

P value

BMI

22.4 ± 4.3 (17.3–28.5)

25.5 ± 4.8 (16.6–39.5)

27.0 ± 4.3 (17.5–38.9)

0.040

Male gender, n (%)

8 (100%)

25 (89.3%)

23 (79.3%)

0.271

Age at outpatient visit (years)

28.3 ± 12.5 (17–54)

35.3 ± 8.8 (21–54)

32.9 ± 7.9 (21–54)

0.143

Age at onset (years)

18.5 ± 3.8 (14–24)

23.0 ± 5.9 (15–38)

25.0 ± 6.1 (15–39)

0.021

Duration of AS (years)

10.0 ± 12.7 (0–37.0)

12.5 ± 10.5 (0.5–37.0)

8.1 ± 6.8 (0–22.0)

0.214

Diagnosis delay (years)

4.6 ± 6.8 (0.0–18.0)

6.11 ± 7.23 (0–27.0)

5.3 ± 7.4 (0–33.0)

0.855

EAMs, n (%)

 Uveitis

0

2 (7.1%)

2 (6.9%)

0.744

 IBD

0

2 (7.1%)

2 (6.9%)

0.744

 Family history, n (%)

3 (37.5%)

7 (25.0%)

4 (13.8%)

0.302

 HLA-B27 positivity, n (%)

8 (100%)

26 (92.9%)

27 (93.1%)

0.744

 Current use of NSAIDs, n (%)

5 (62.5%)

16 (57.1%)

22 (75.9%)

0.325

 Current use of DMARDs, n (%)

5 (62.5%)

12 (42.9%)

18 (62.1%)

0.308

 ESR (mm)

30.9 ± 21.2 (2–65)

35.8 ± 21.6 (3–93)

28.3 ± 18 (8–91)

0.383

 CRP (mg/L)

19.2 ± 10.9 (3.5–35.2)

33.4 ± 32.9 (3.2–133.0)

22.5 ± 22.8 (1.9–100.0)

0.222

 hsCRP (mg/L)

16.8 ± 13.2 (0.1–34.2)

31.9 ± 34.9 (0.8–137.4)

21.8 ± 24.2 (0.2–114.6)

0.277

 BASDAI

3.9 ± 1.8 (1.4–5.8)

4.3 ± 2.0 (0.6–8.4)

3.1 ± 2.1 (0.4–7.8)

0.094

 BASFI

2.4 ± 1.7 (0.5–5.5)

2.4 ± 1.7 (0.3–6.3)

1.8 ± 1.3 (0.2–4.0)

0.269

 SF-12 PCS

35.1 ± 15.5 (16.5–58.4)

34.9 ± 11.6 (18.2–55.4)

40.7 ± 11.0 (18.5–55.9)

0.158

 SF-12 MCS

36.1 ± 15.9 (17.1–55.4)

37.4 ± 11.6 (20.3–57.9)

42.2 ± 10.0 (21.4–55.9)

0.197

 ASQOL

7.5 ± 5.9 (2–17)

7.0 ± 4.2 (1–16)

5.5 ± 4.2 (0–14)

0.344

 HHS

72.5 ± 27.9 (24–100)

68.6 ± 20.8 (36–100)

83.6 ± 13.1 (48–99)

0.013

 BASRI-Hip

1.9 ± 1.3 (0–3)

2.5–1.3 (0–4)

1.2 ± 1.2 (0–4)

0.002

 CFI

3.4 ± 1.0 (1.7–4.8)

3.5 ± 0.9 (2.2–5.8)

3.6 ± 0.7 (2.1–5.0)

0.763

 MCFI

2.1 ± 0.3 (1.8–2.7)

2.2 ± 0.2 (1.8–2.6)

2.2 ± 0.3 (1.3–3.0)

0.766

 CBR

0.4 ± 0.1 (0.3–0.6)

0.5 ± 0.1 (0.3–0.7)

0.4 ± 0.1 (0.3–0.6)

0.094

 CCR

0.5 ± 0.2 (0.36–0.9)

0.5 ± 0.1 (0.3–0.8)

0.5 ± 0.1 (0.3–0.7)

0.768

  1. The value of continuous variables was presented as mean ± standard deviation and the categorical variables were based on presented as number plus percentage
  2. Abbreviations: OP Osteoporosis, BMI Body mass index, AS Ankylosing spondylitis, EAMs Extra-articular manifestations, IBD Inflammatory bowel disease, NSAIDs Nonsteroidal anti-inflammatory drugs, DMARDs Disease modifying antirheumatic drugs, ESR Erythrocyte sedimentation rate, CRP C reactive protein, hsCRP High sensitive C reactive protein, BASDAI Bath ankylosing spondylitis disease activity index, BASFI Bath ankylosing spondylitis functional index, SF-12 PCS Short form-12 physical component summary, SF-12 MCS Short form-12 mental component summary, ASQOL Ankylosing spondylitis quality of life, HHS Harris hip score, BASRI-Hip The bath ankylosing spondylitis radiology hip index
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us